Apogee Therapeutics CEO sells shares price $732,692

Michael Thomas Henderson, the Chief Government Officer of Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ:APGE), lately bought shares of the corporate, in response to a submitting with the Securities and Change Fee. The transactions, executed on January 8, 2025, have been a part of a pre-arranged buying and selling plan below Rule 10b5-1. The sale comes because the $2.8 billion market cap firm maintains a GREAT monetary well being rating, in response to InvestingPro information.

Henderson bought a complete of 15,000 shares of widespread inventory in two separate transactions. The shares have been bought at a weighted common value, with the primary batch of 12,132 shares bought at costs starting from $48.20 to $49.15, and the second batch of two,868 shares bought at costs starting from $49.35 to $49.45. This resulted in a complete transaction worth of $732,692. The inventory has since declined 14% up to now week to $41.05, although analysts keep value targets starting from $80 to $110.

Following these gross sales, Henderson retains direct possession of 1,309,487 shares within the firm. These transactions have been carried out below a buying and selling plan adopted on September 25, 2023. Primarily based on InvestingPro‘s Truthful Worth evaluation, the inventory seems overvalued at present ranges, with 8 extra ProTips out there for subscribers.

In different current information, Apogee Therapeutics maintains a robust monetary place, backed by $790 million in property, with analysts from Guggenheim, Stifel, and BTIG sustaining their Purchase rankings. Guggenheim has ratcheted up its value goal to $110, lauding Apogee’s strategic deal with validated targets and optimized trial design. Latest medical trial failures by rivals within the atopic dermatitis house have been seen as a optimistic, probably lowering competitors for Apogee.

The corporate’s ongoing Part 1 medical trial of APG777, a therapy for moderate-to-severe atopic dermatitis, has proven promising outcomes. As well as, Apogee has initiated a Part 1 trial for APG990, with interim information anticipated in 2025. These developments are a part of Apogee’s broader analysis and improvement technique, which has been recommended by Guggenheim.

When it comes to company progress, Apogee has appointed Jeff S. Hartness as the brand new Chief Industrial Officer, and Dr. Lisa Bollinger has joined the board of administrators. These current developments underscore Apogee’s continued progress in drug improvement and company progress. These are the current developments at Apogee Therapeutics.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.